Prot #INCB 18424-357: Polycythemia Vera Symptom Study Evaluating Ruxolitinib Versus Hydroxyurea in a Randomized, Multicenter, Double-Blind, Double-Dummy, Phase 3 Efficacy and Safety Study of Patient Reported Outcomes

Project: Research project

Project Details

StatusFinished
Effective start/end date1/17/13 → 1/17/19

Funding

  • PharmaNet, Inc. (Prot #INCB 18424-357 // Prot #INCB 18424-357)
  • Incyte Corporation (Prot #INCB 18424-357 // Prot #INCB 18424-357)